XM-ONE identifies patients at risk
XM-ONE, AbSorber's transplantation cross match, has been suggested to identify patients at risk of experiencing acute rejections after kidney transplantation. This was initially shown in 2009 when Breimer and co-workers published data from a multicenter study XM-ONE® (Breimer, M et al, Transplantation, Feb 2009). In a new publication from Johns Hopkins Medical School, Baltimore, MD (Jackson, AM et al, Transplantation, Apr 2011) these findings are confirmed.
AbSorber AB is a biotech company focused on developing products that increase the probability of transplantation success. XM-ONE®, the first AbSorber product on the market, is a CE-marked and FDA registered non-HLA transplantation crossmatch test kit. In contrast to current crossmatch testing, XM-ONE® rapidly detects antibodies specific for endothelial-specific antigens (AECA) as well as antibodies specific to major transplantation antigens. read more»
Olerup will be presenting the product line at EFI 2013.
Come and visit the booth to learn more about XM-ONE.
May 11-14, 2013
|Location:||Maastricht, The Netherlands|